Trial · NCT02714205

Flushing Reduction Associated With Nitrates

NCT02714205, Phase 2, Completed, Alison Huang, MD; results first posted 2023-05-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Flushing Reduction Associated With Nitrates. Trials, record NCT02714205. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02714205

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Flushing Reduction Associated With Nitrates
NCT number: NCT02714205
Status: Completed
Phases: Phase 2
Enrollment: 141 participants, actual
Lead sponsor: Alison Huang, MD
Conditions: Menopausal Hot Flashes
Interventions: transdermal nitroglycerin, Placebo
First posted: 2016-03-21
Last updated: 2025-03-28
Results first posted: 2023-05-18

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline Hot Flash Frequency	Repeated change from baseline to 5 and 12 weeks	Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points.
Secondary	Change From Baseline Hot Flash Related Daily Interference Scale (HFRDIS) Score	Repeated change from baseline to 5 and 12 weeks	Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. Range 0-100, Higher score indicates lower quality of life
Secondary	Change From Baseline Menopause Quality of Life (MENQOL), Vasomotor Domain Score	Repeated change from baseline to 5 and 12 weeks	Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. Range 1-8, Higher score indicates lower quality of life
Secondary	Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score	Repeated change from baseline to 5 and 12 weeks	Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-21, Higher score indicates lower quality of life
Secondary	Change From Baseline Generalized Anxiety Disorder-7 (GAD-7) Score	Repeated change from baseline to 5 and 12 weeks	Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-21, Higher score indicates lower quality of life
Secondary	Change From Baseline Center for Epidemiologic Studies Depression (CES-D) Score	Repeated change from baseline to 5 and 12 weeks	Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points Range 0-60, a higher score indicates a lower quality of life.
Secondary	Change in Baseline Frequency of Moderate-to-severe Hot Flashes	Repeated change from baseline to 5 and 12 weeks	Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points
Secondary	Change in Baseline Total Hot Flash Severity Score	Repeated change from baseline to 5 and 12 weeks	Change was calculated as the followup value minus the baseline value. Values are model generated Least Square Means for combined 5 and 12 month time points. The hot flash severity score is calculated as the sum of severity ratings for all hot flashes recorded on the symptom over a 7-day period (mild=1, moderate=2, severe=3), and then divided by 7 for the daily average score. Range 12-60, higher score indicates lower quality of life.
Other	Number of Participants With Treatment Related Severe Adverse Events Defined by Common Terminology Criteria for Adverse Events (CTCAE) Severity Grade 3 or Higher.	Baseline to 12 weeks	Number of participants with treatment related severe adverse events defined by Common Terminology Criteria for Adverse Events (CTCAE) severity grade 3 or higher.

Source ClinicalTrials.gov

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change From Baseline Hot Flash Frequency	Repeated change from baseline to 5 and 12 weeks	Hot flashes per day	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline Hot Flash Related Daily Interference Scale (HFRDIS) Score	Repeated change from baseline to 5 and 12 weeks	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline Menopause Quality of Life (MENQOL), Vasomotor Domain Score	Repeated change from baseline to 5 and 12 weeks	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score	Repeated change from baseline to 5 and 12 weeks	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline Generalized Anxiety Disorder-7 (GAD-7) Score	Repeated change from baseline to 5 and 12 weeks	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline Center for Epidemiologic Studies Depression (CES-D) Score	Repeated change from baseline to 5 and 12 weeks	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change in Baseline Frequency of Moderate-to-severe Hot Flashes	Repeated change from baseline to 5 and 12 weeks	Hot flashes per day	LEAST_SQUARES_MEAN
SECONDARY	Change in Baseline Total Hot Flash Severity Score	Repeated change from baseline to 5 and 12 weeks	units on a scale	LEAST_SQUARES_MEAN
OTHER_PRE_SPECIFIED	Number of Participants With Treatment Related Severe Adverse Events Defined by Common Terminology Criteria for Adverse Events (CTCAE) Severity Grade 3 or Higher.	Baseline to 12 weeks	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline Hot Flash Frequency	Transdermal Nitroglycerin	-4.56	95% Confidence Interval -6.01 to -3.11	Hot flashes per day
Change From Baseline Hot Flash Frequency	Placebo	-4.02	95% Confidence Interval -5.41 to -2.63	Hot flashes per day
Change From Baseline Hot Flash Related Daily Interference Scale (HFRDIS) Score	Transdermal Nitroglycerin	-19.85	95% Confidence Interval -28.5 to -11.2	units on a scale
Change From Baseline Hot Flash Related Daily Interference Scale (HFRDIS) Score	Placebo	-20.36	95% Confidence Interval -28.61 to -12.12	units on a scale
Change From Baseline Menopause Quality of Life (MENQOL), Vasomotor Domain Score	Transdermal Nitroglycerin	-1.53	95% Confidence Interval -2.42 to -0.64	units on a scale
Change From Baseline Menopause Quality of Life (MENQOL), Vasomotor Domain Score	Placebo	-1.33	95% Confidence Interval -2.17 to -0.49	units on a scale
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score	Transdermal Nitroglycerin	-1.27	95% Confidence Interval -2.23 to -0.31	score on a scale
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score	Placebo	-1.18	95% Confidence Interval -2.1 to -0.26	score on a scale
Change From Baseline Generalized Anxiety Disorder-7 (GAD-7) Score	Transdermal Nitroglycerin	-0.15	95% Confidence Interval -1.18 to 0.89	units on a scale
Change From Baseline Generalized Anxiety Disorder-7 (GAD-7) Score	Placebo	-0.57	95% Confidence Interval -1.56 to 0.42	units on a scale

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Transdermal Nitroglycerin	70
Overall Study	STARTED	Placebo	71
Overall Study	COMPLETED	Transdermal Nitroglycerin	66
Overall Study	COMPLETED	Placebo	70
Overall Study	NOT COMPLETED	Transdermal Nitroglycerin	4
Overall Study	NOT COMPLETED	Placebo	1

Source ClinicalTrials.gov

Adverse events124

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Heart Fluttering	Cardiac disorders	Transdermal Nitroglycerin	0	70	0
other	Heart Fluttering	Cardiac disorders	Placebo	1	71	1
other	Palpitations	Cardiac disorders	Transdermal Nitroglycerin	1	70	1
other	Palpitations	Cardiac disorders	Placebo	1	71	1
other	Vertigo	Ear and labyrinth disorders	Transdermal Nitroglycerin	1	70	1
other	Vertigo	Ear and labyrinth disorders	Placebo	1	71	1
other	Diarrhea	Gastrointestinal disorders	Transdermal Nitroglycerin	0	70	0
other	Diarrhea	Gastrointestinal disorders	Placebo	1	71	1
other	Dry Mouth	Gastrointestinal disorders	Transdermal Nitroglycerin	0	70	0
other	Dry Mouth	Gastrointestinal disorders	Placebo	1	71	1

1 to 10 of 124Source ClinicalTrials.gov

See all 124 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Transdermal Nitroglycerin	0	70
Total, all-cause mortality	Placebo	0	71
Total, other adverse events	Transdermal Nitroglycerin	65	70
Total, other adverse events	Placebo	66	71
Total, serious adverse events	Transdermal Nitroglycerin	0	70
Total, serious adverse events	Placebo	0	71

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37273224	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01AG050588	Transdermal Nitroglycerin Therapy for Menopausal Hot Flashes	HUANG, ALISON	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	NATIONAL INSTITUTE ON AGING	2016 to 2019

Source NIH RePORTER

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Transdermal Nitroglycerin vs Placebo: Number of Participants With Treatment Related Severe Adverse Events Defined by Common Terminology Criteria for Adverse Events (CTCAE) Severity Grade 3 or Higher.	Trial comparisons
Transdermal Nitroglycerin vs Placebo: deaths from any cause	Trial comparisons
Transdermal Nitroglycerin vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02714205

GET https://conductscience.org/api/trials/v1/NCT02714205/events?page=2

API reference For AI assistants